Acticor Biotech
Bérengère Hennebelle, Pharm.D, has 20 years of experience in the pharmaceutical industry. She began her career in pharmaceutical development services in medium-sized companies (Guerbet, HRA Pharma), combining CMC development and technical-regulatory activities on an international scale. After a university degree in biological therapies, she turned to biotechnological products. She contributed to the CMC strategy and coordinated CMC dossiers of biologics in the FDA and EMA registration phase for a recombinant protein at LFB and then for a gene therapy product at Gensight Biologics. She joined Acticor in 2022 to take over CMC regulatory activities.
This person is not in any offices
Acticor Biotech
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.